Literature DB >> 16995332

Differences between prescribed daily doses and defined daily doses of antiepileptics--therapeutic drug monitoring as a marker of the quality of the treatment.

B Koristkova1, M Grundmann, H Brozmanova.   

Abstract

OBJECTIVE: Prescribed daily doses (PDDs) of antiepileptics (N03A ATC group) were recorded for drugs used in monotherapy or in combination therapy in the University Hospital in Ostrava, Czechia. Plasma levels were used as an indicator of the quality of treatment.
METHOD: Request and reply forms for therapeutic drug monitoring (TDM) were used as a source of PDDs and plasma levels. The study included 1,144 in-patients examined in the period 1993 - 2004. The differences in PDD were tested by Mann-Whitney-U-test. ATC/DDD index 2005 was used. Doses given in mono- and polytherapy were compared.
RESULTS: Median PDDs in samples within the therapeutic range (in mg) in mono-/polytherapy were as follows (DDDs in parenthesis): carbamazepine 600/800 (1,000), clonazepam 2.0/2.0 (8), phenytoin 300/300 (300), ethosuximide -/1000 (1,250), lamotrigine 250/200 (300), phenobarbital -/200 (100), primidone 500/625 (1,250), topiramate -/300 (300), valproic acid 750/1,000 (1,500). Median PDDs in polytherapy with antiepileptics not analyzed for TDM were: gabapentin 900 (1,800), levetiracetam 1,500 (1,500), vigabatrin 1,500 (2,000).
CONCLUSIONS: PDDs in monotherapy were similar or slightly lower than in combination therapy with an exception for lamotrigine, NS. The differences were significant in carbamazepine, p < 0.0001, and valproic acid, p < 0.001. Patients with plasma levels within the therapeutic range were usually treated with similar or slightly higher doses than the remainder. In polytherapy the PDDs were similar to DDDs in carbamazepine, ethosuximide, phenytoin, and topiramate in samples within the therapeutic range when difference +/- 20 per cent was considered as acceptable PDD of levetiracetam was also similar to actual DDD. In general plasma levels tended to be below the therapeutic range. The differences between PDD and DDD of antiepileptics have to be taken into account especially when utilization of different drugs is compared.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16995332     DOI: 10.5414/cpp44438

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  7 in total

1.  Analyzing U.S. prescription lists with RxNorm and the ATC/DDD Index.

Authors:  Olivier Bodenreider; Laritza M Rodriguez
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

2.  Hospital statistics for antibiotics: defined versus prescribed daily dose.

Authors:  C Gagliotti; E Ricchizzi; R Buttazzi; F Tumietto; D Resi; M L Moro
Journal:  Infection       Date:  2014-06-29       Impact factor: 3.553

3.  Correlation between prescribed daily dose, seizure freedom and defined daily dose in antiepileptic drug treatment.

Authors:  László Horváth; Klára Fekete; Sándor Márton; István Fekete
Journal:  Int J Clin Pharm       Date:  2017-03-02

4.  Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?

Authors:  Thomas Grimmsmann; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2011-03-10       Impact factor: 2.953

5.  [Therapeutic drug monitoring of three antiepileptic drugs - Back on twenty years of experience].

Authors:  Samira Serragui; Fatima Zalagh; Driss Soussi Tanani; Lahcen Ouammi; Latifa Ait Moussa; Narjis Badrane; Rachida Soulaymani Bencheikh
Journal:  Pan Afr Med J       Date:  2016-09-19

6.  Prescription Pattern of Antihypertensive Drugs: An Experience from a Secondary Care Hospital in the United Arab Emirates.

Authors:  Maryam Salem Alkaabi; Syed Arman Rabbani; Padma G M Rao; Syed Rashid Ali
Journal:  J Res Pharm Pract       Date:  2019 Apr-Jun

7.  Drug utilisation study in a tertiary care center: recommendations for improving hospital drug dispensing policies.

Authors:  Niti Mittal; R Mittal; I Singh; Nusrat Shafiq; S Malhotra
Journal:  Indian J Pharm Sci       Date:  2014-07       Impact factor: 0.975

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.